30 completed, 13 unknown, 8 active not recruiting, 8 recruiting. 42 Phase 2, 16 Phase 3, 11 Phase 1, 2 Not applicable, 1 Early Phase 1.
Follow FOLFOX regimen: new trials by email Literature Review of FOLFOX regimen trials Research Report on FOLFOX regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test Capecitabine, Oxaliplatin, Folfirinox - Colorectal Cancer | Phase 3 | Active not recruiting | UNICANCER | 2450 | 2026-07-20 | 2026-07-22 |
| Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | BinYong Liang | 100 | 2026-04-30 | 2026-04-13 |
| Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma Ivonescimab, FOLFOX regimen, Irinotecan - Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma | Phase 2 | Recruiting | UNICANCER | 88 | 2025-11-20 | 2026-04-28 |
| Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients Ivonescimab, FOLFOX regimen - Biliary Tract Cancer | Phase 2 | Recruiting | UNICANCER | 72 | 2025-10-09 | 2026-08-28 |
| A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies M3T01, Pembrolizumab, Chemoradiation - Advanced Solid Tumors | Phase 1 | Recruiting | Providence Health & Services | 110 | 2025-06-17 | 2026-07-23 |
| Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme FOLFOX regimen, CAPOX regimen - Digestive Cancer, Colorectal Cancer | Phase 2 | Recruiting | UNICANCER | 400 | 2025-01-20 | 2026-04-23 |
| First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer Nivolumab, FOLFOX regimen, EXL01 - Gastric Cancer | Phase 2 | Recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 120 | 2024-04-16 | 2025-09-22 |
| Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer Immune checkpoint inhibitor, FOLFOX regimen - Locally Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 170 | 2023-11-01 | 2025-11-28 |
| Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA) Radiation Therapy, FOLFOX regimen, Capecitabine - Colorectal Carcinoma | Phase 2 | Recruiting | Neil Kopek | 35 | 2023-08-16 | 2025-05-28 |
| Immunotherapy for Advanced Liver Cancer AlloStim® immunotherapy, FOLFOX regimen, Sorafenib - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Suspended | Mirror Biologics, Inc. | 150 | 2023-08-01 | 2025-10-23 |
| Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer Taurine, Sintilimab, XELOX regimen - Gastric Cancer | Phase 2 | Unknown | Tang-Du Hospital | 60 | 2023-08-01 | 2023-11-08 |
| Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer Trifluridine/Tipiracil, Oxaliplatin, FOLFOX regimen - Gastric Adenocarcinoma, Esophagus Adenocarcinoma | Phase 2 | Active not recruiting | UNICANCER | 118 | 2023-06-23 | 2026-07-24 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab Irinotecan, FOLFOX regimen, Bevacizumab - Colorectal Cancer, Peritoneal Metastases | Phase 2 | Unknown | Catharina Ziekenhuis Eindhoven | 85 | 2022-12-27 | 2023-08-22 |
| Immunosurveillance for Metastatic Colorectal Cancer Adenorine, Placebo, FOLFOX regimen - Monitoring, Immunologic | Phase 2 / Phase 3 | Completed | MIPO Clinic | 187 | 2022-07-15 | 2026-06-29 |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy Regorafenib, Nivolumab, CapeOX - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Completed | National Cancer Center Hospital East | 30 | 2022-06-06 | 2026-04-09 |
| PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma PM8002, FOLFOX regimen - Hepatocellular Carcinoma | Phase 2 | Completed | Biotheus Inc. | 35 | 2022-04-22 | 2026-07-09 |
| A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. Etrumadenant (AB928), Radiation therapy, FOLFOX regimen - Rectal Cancer | Phase 2 | Recruiting | Weill Medical College of Cornell University | 43 | 2022-03-31 | 2026-07-29 |
| Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma Capecitabine, Radiation Therapy, FOLFOX regimen - Rectal Adenocarcinoma | Early Phase 1 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2021-12-23 | 2026-04-01 |
| CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen Cetuximab, FOLFIRI, FOLFOX regimen - Metastatic Colorectal Adenocarcinoma | Phase 2 | Active not recruiting | University of Campania Luigi Vanvitelli | 219 | 2021-07-15 | 2025-05-25 |
Showing 20 of 66. Sign in to see all of them.
Colorectal Neoplasms (38) · Colonic Neoplasms (27) · Rectal Neoplasms (26) · Neoplasm Metastasis (9) · Adenocarcinoma Of Esophagus (5) · Stomach Neoplasms (5) · Carcinoma, Hepatocellular (4) · Neoplasms (3) · Adenocarcinoma (2) · Cholangiocarcinoma (2) · Esophageal Neoplasms (2) · Gastrointestinal Neoplasms (2) · Liver Neoplasms (2) · Recurrence (2) · Bile Duct Neoplasms (1)
UNICANCER (7) · GERCOR - Multidisciplinary Oncology Cooperative Group (5) · National Cancer Institute (NCI) (4) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Genentech, Inc. (2) · Medical Research Council (2) · Memorial Sloan Kettering Cancer Center (2) · Stanford University (2) · Washington University School of Medicine (2) · Abramson Cancer Center at Penn Medicine (1) · Alliance for Clinical Trials in Oncology (1) · Amgen (1) · BinYong Liang (1) · Biotheus Inc. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)
United States (27) · France (18) · United Kingdom (6) · China (5) · Canada (4) · Italy (4) · Austria (3) · Belgium (3) · Germany (3) · Netherlands (3) · Spain (3) · Sweden (3) · Norway (2) · Portugal (2) · Australia (1)
Aimery de Gramont, MD (2) · Matthew T. Seymour, MA, MD, FRCP (2) · Nancy E. Kemeny, MD (2) · Wolf O. Bechstein, MD (2) · Alexander Stojadinovic, MD (1) · Alfredo Carrato, MD, PhD (1) · Ann M. Mauer, MD (1) · Bernard Nordlinger, MD (1) · Branimir I. Sikic, MD (1) · Chia Portera, M.D. (1) · David Malka, MD (1) · Encouse Golden, M.D., Ph.D. (1)
PMID 12229948, PMID 12860947, PMID 15383798, PMID 15496622, PMID 15623449, PMID 15868235, PMID 16009951, PMID 16009952, PMID 16110021, PMID 16177017, PMID 16813588, PMID 16877722, PMID 16971718, PMID 16983741, PMID 17008704, PMID 17175450, PMID 17630037, PMID 17785765, PMID 17968156, PMID 18358928, PMID 18452860, PMID 18981005, PMID 19233901, PMID 19269519, PMID 19554377, PMID 19858398, PMID 19884549, PMID 20395841, PMID 20632311, PMID 20692872, PMID 21570111, PMID 21596621, PMID 21831177, PMID 21859417, PMID 22067400, PMID 22070868, PMID 22314329, PMID 22431703, PMID 22539154, PMID 24120480, PMID 24495589, PMID 26032776, PMID 26049686, PMID 26156652, PMID 26342674, PMID 27843597, PMID 28209746, PMID 28449055, PMID 29620995, PMID 29627309
2023 (2), 2009 (1), 2017 (1), 2018 (1), 2025 (1), N01CM62206 (1), P30CA008748 (1), P30CA016087 (1), P30CA033572 (1), U01CA069856 (1), U10CA032102 (1)